亚太膀胱疾病市场 – 行业趋势及 2029 年预测

亚太膀胱疾病市场分析与洞察 

膀胱疾病是一组会影响人类日常生活的疾病。一些最常见的膀胱疾病是膀胱炎（膀胱感染并引起炎症）。尿失禁（失去膀胱控制）、间质性膀胱炎（膀胱疼痛和频繁、紧迫排尿）和膀胱过度活动症（膀胱挤压尿液的一种情况）。膀胱疾病会影响生活质量并导致其他健康问题。健康变化和问题（包括神经系统和生活方式因素）可能导致或加剧男性和女性的 UI。

最常见的膀胱疾病是膀胱过度活动症和尿失禁。这些问题与神经系统有关。神经将信息从大脑传递到膀胱，指示肌肉收缩或释放。大脑决定排尿的可接受时间，当从大脑获取信息时出现问题时，就会发生尿失禁。健康变化和问题可能导致尿失禁，包括衰老、膀胱感染、便秘、糖尿病和超重等

亚太地区膀胱疾病市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 13.1%，预计到 2029 年将达到 52.8011 亿美元。

Market Definition of Asia-Pacific Bladder Disorders Market

Bladder related disorders include Cystitis - inflammation of the bladder, often from an infection, Urinary incontinence - loss of bladder control, Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.

Different tests are performed by the doctors to diagnose the bladder disorder that includes x-rays, urine tests, and a bladder wall examination by scope called cystoscope. The treatment of the disorder depends on the cause of the problem and the treatment includes medication, surgeries (in severe cases), and non-surgical procedures.

Anticholinergic medications are the first-line of pharmacotherapy in Overactive Bladder (OAB) syndrome. OAB is a clinical symptom characterized by urgency of desire to urine pass, which is difficult to defer, generally frequency to pass urine more than eight times per day are consider into OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle that reduce the bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.

Asia-Pacific Bladder Disorders Market Dynamics

Drivers

• STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

Bladder disorders are a number of bladder issues that can affect daily physical activities. The most common bladder disorders are cystitis, interstitial cystitis, overactive bladder, urinary incontinence, and bladder cancer. Most bladder issues are caused by a bacterial infection that enters the urinary tract.

Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, allow them to increase their company's product portfolio, leading to market expansion and hence enhancing the product demand among customers, which ultimately provides the market players to earn maximum revenue.

• GROWING GERIATRIC POPULATION

Aging is a strong risk factor that can associate with bladder-related disorders. Aging prompts neurologic, anatomic, and biochemical changes in bladder function, which can dispose to the development of OAB and Overactive bladder is the most common problem among the geriatric population. Aging population is suffering from various bladder-associated problems and disorders due to which they are the predominant users of chronic health management services and solutions.

According to the noble study, the prevalence rate of overactive bladder is approximately 16.9 in women and men, around 16.0%, and the prevalence of OAB is growing with age. However, treatment guidelines specify the preferred first-, second-, and third-line OAB therapy strategies. Bladder disorders are associated with the Neurologic disorders such as dementia and in this age group OAB is very challenging for the senior population. Over the last few decades, the old age population has been drastically growing worldwide.

• RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

Nowadays, various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to launch during the forecast period.

• COMBINATION OF DIFFERENT TARGET THERAPIES

Combination Therapies are much more effective than monotherapy, without additional side effects. Combination Therapies are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieve patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Opportunities

• SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners.

Bladder disorder management now emphasizes assisting patients with various alternatives for self-care and a range of consultation services to educate patients about their illness state and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism.

Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases to enhance patient outcomes.

• RISING DISEASE MANAGEMENT PROGRAMS

People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems and increasing healthcare expenditures has encouraged better healthcare plans.

Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.

Restraints/Challenges

However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.

This Asia-Pacific bladder disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific bladder disorders market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Post COVID-19 Impact on Asia- Pacific Bladder Disorders Market

COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market

Recent Development

• 4 月，Axonics, Inc. 宣布在美国全面推出 Axonics F15，该公司正在开发和商业化用于治疗膀胱和肠道功能障碍的新产品。该公司的此次发布扩大了其产品组合，从而增加了未来的销售和需求。

亚太膀胱疾病市场范围

亚太膀胱疾病市场分为类型、治疗类型、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。

类型

• 膀胱炎
• 尿失禁
• 膀胱过度活动症
• 间质性膀胱炎
• 膀胱癌

根据类型，亚太膀胱疾病市场分为膀胱炎、尿失禁、膀胱过度活动症、间质性膀胱炎和膀胱癌。

治疗类型

• 外科手术
• 药物
• 其他的

根据产品，亚太膀胱疾病市场分为手术、药物和其他。

最终用户

• 医院
• 诊所
• 门诊手术中心
• 其他的

根据最终用户，亚太膀胱疾病市场分为医院、诊所、门诊手术中心和其他。

分销渠道

• 直接的
• 零售

根据分销渠道，亚太膀胱疾病市场分为直接分销和零售分销。

亚太膀胱疾病市场区域分析/见解    

对亚太地区膀胱疾病市场进行了分析，并按国家、类型、治疗类型、最终用户和分销渠道提供了市场规模洞察和趋势，如上所述。

该市场覆盖的国家包括中国、日本、印度、韩国、澳大利亚、新加坡、泰国、马来西亚、印度尼西亚、菲律宾、越南和亚太其他地区。

中国在市场份额和收入方面占据亚太膀胱疾病市场的主导地位，并将在预测期内继续保持主导地位。这是由于该地区膀胱过度活动症的患病率很高，而不断增长的研发投资和新疗法的推出正在推动市场的发展

报告的国家部分还提供了影响单个市场因素和市场法规变化的信息，这些因素和变化会影响市场的当前和未来趋势。新车和替代车销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测单个国家市场情况的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了亚太地区品牌的存在和可用性以及它们因本土和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。

竞争格局和亚太膀胱疾病市场份额分析

亚太膀胱疾病市场竞争格局提供了有关竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、亚太地区业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上数据点仅与公司对亚太膀胱疾病市场的关注有关。

亚太地区膀胱疾病市场的一些主要参与者包括美敦力、Laborie、波士顿科学公司、辉瑞公司、安斯泰来制药公司、KYORIN 制药有限公司（KYORIN Holdings, Inc. 的子公司）、百时美施贵宝公司、强生服务公司、Axonics, Inc.、默克公司、Viatris Inc.、Gaylord Chemical Company, LLC、Coloplast Corp、艾伯维公司、太阳制药工业有限公司、Zydus Group、Swati Spentose、Urovant Sciences 等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、亚太地区与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们很自豪能够为现有和新客户提供符合其目标的数据和分析。报告可以定制，包括目标品牌的价格趋势分析、对其他国家市场（索取国家名单）的了解、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿

SKU-69072